Price$0.63-0.00 (-0.57%)
02:00 PM03:15 PM
News · 26 weeks41-75%
2025-12-142026-06-07
Mix2090d
- SEC Filings11(55%)
- Other8(40%)
- Insider1(5%)
Latest news
25 items- SECSEC Form S-3 filed by Genprex Inc.S-3 - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual MeetingTrop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract details positive clinical data from studies of predicti
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingPdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four WeeksAUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data on the Company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy, PM or GPX-002) can reverse hyperglycemia in Type 2 dia
- SECSEC Form 10-Q filed by Genprex Inc.10-Q - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerStrengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Israel Patent Office (ILPO) has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. "Securing this patent in Israel further solidifies Genprex's robust
- SECSEC Form DEF 14A filed by Genprex Inc.DEF 14A - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual MeetingPdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four WeeksAUSTIN, Texas, April 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data on the Company's diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, Mass. The collaborators will present preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene t
- PRPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual MeetingAUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.
- SECGenprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyResearch on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA TreatmentDemonstrates Commitment to Tailored Treatment Options for Patients With Unmet Medical NeedAUSTIN, Texas, April 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company has entered into a new Sponsored Research Agreement (SRA) with The University of Texas MD Anderson Cancer Center (UT MD Anderson) to study biomarkers that may predict patient response to Reqorsa® Gene Th
- PRGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingTROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo Mouse StudiesREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, April 20, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, Californ
- SECSEC Form PRE 14A filed by Genprex Inc.PRE 14A - Genprex, Inc. (0001595248) (Filer)
- INSIDERSEC Form 4 filed by Longnecker Brent M4 - Genprex, Inc. (0001595248) (Issuer)
- SECSEC Form 10-K filed by Genprex Inc.10-K - Genprex, Inc. (0001595248) (Filer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual MeetingResearch Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyREQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, March 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators
- PRGenprex to Participate at BIO Europe Spring 2026AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal. In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throug
- INSIDERChief Medical Officer Berger Mark Stanley covered exercise/tax liability with 7,168 shares, decreasing direct ownership by 25% to 21,692 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)
- INSIDERPresident, CEO and CFO Confer Ryan M. covered exercise/tax liability with 9,330 shares, decreasing direct ownership by 20% to 36,331 units (SEC Form 4)4 - Genprex, Inc. (0001595248) (Issuer)
- SECGenprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Genprex, Inc. (0001595248) (Filer)
- PRGenprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat CancerJapanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq® AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex
GNPX FAQ
6 questionsWhat does Genprex Inc. do?
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell...Where does GNPX stock trade?
Genprex Inc. (GNPX) is listed on NASDAQ.What sector and industry is GNPX in?
Genprex Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genprex Inc. go public?
Genprex Inc. (GNPX) completed its IPO in 2018.What companies are similar to GNPX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GNPX side-by-side with any of them on Quantisnow.How can I track GNPX on Quantisnow?
Quantisnow aggregates Genprex Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNPX to receive live email and push alerts on every new disclosure.